Market closed
Acelyrin/$SLRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Acelyrin
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
Ticker
$SLRN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
83
Website
Acelyrin Metrics
BasicAdvanced
$222M
-
-$2.50
-
-
Price and volume
Market cap
$222M
52-week high
$2.95
52-week low
$2.03
Average daily volume
965K
Financial strength
Current ratio
18.097
Quick ratio
17.076
Long term debt to equity
1.368
Total debt to equity
1.594
Management effectiveness
Return on assets (TTM)
-29.73%
Return on equity (TTM)
-44.54%
Valuation
Price to book
0.48
Price to tangible book (TTM)
0.48
Price to free cash flow (TTM)
-0.716
Growth
Earnings per share change (TTM)
-53.99%
3-year earnings per share growth (CAGR)
-65.50%
Acelyrin News
AllArticlesVideos
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
Business Wire·3 days ago
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
GlobeNewsWire·1 month ago
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Acelyrin stock?
Acelyrin (SLRN) has a market cap of $222M as of April 19, 2025.
What is the P/E ratio for Acelyrin stock?
The price to earnings (P/E) ratio for Acelyrin (SLRN) stock is 0 as of April 19, 2025.
Does Acelyrin stock pay dividends?
No, Acelyrin (SLRN) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Acelyrin dividend payment date?
Acelyrin (SLRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Acelyrin?
Acelyrin (SLRN) does not currently have a Beta indicator.